[Transfer] Large -scale pharmaceutical companies, executives resign frequently

[Transfer] Large -scale pharmaceutical companies, executives resign frequently

Source: Sai Bailan/Taotao

1, 35 executives resign

In June, the flow of senior management of pharmaceutical companies continued, from BIOTECH Popular Shenzhou to traditional major pharmaceutical companies, Harbao, Northeast Pharmaceuticals, to well -known Chinese medicine pharmaceutical companies, Huayu, Guangyuyuan, Yiling Pharmaceutical, etc. 35 people.

Entering 2022, the major pharmaceutical companies have adjusted frequently, the grass -roots employees have reduced the news of the departure of the executives. In April, 34 senior pharmaceutical company executives left.

Recently, Liu Yan, the former vice president of Baiji Shenzhou and the head of marketing in Greater China, left less than one month after leaving, and has quickly joined Pan Shengzi as chief business officer on July 1 to fully take responsibility for the tumor diagnosis business.

In addition to the reasons for personal development, the departure of executives also reflects the impact of changes in industry policy environment and internal adjustment on executives.

In the recent period of time, the personnel of the Parksan Shenzhou have changed a lot, and core technical executives have resigned in less than a year. In October 2021, Wu Qingyi, the chief business officer of Greater China, left Baiji to join Dzhe Pharmaceutical as the chief business officer; in February 2022, Yong Yong resigned as chief medical officer of immune and oncology; in March 2022, Huang Weijuan resigned as chief hematology chief The post of medical officer, then Liu Yan left in June.

As an innovative enterprise, the successive running of core technicians has also aroused high attention from investors.

In March of this year, when Huang Weijuan left, investors asked, "The company's core technicians resigned continuously. They are the heroes of the three major independent research and development products on the market and Ociperlimab. For workers in the production line, the cost of correction is great. "

At that time, Baiji Shenzhou replied that the adjustment of core technical personnel would not have a significant adverse effect on the research and development of core product research and development. The overall product development and core technology development of the enterprise based on the overall collaboration and overall operation of the entire R & D team. Technical personnel) Situation. The professional knowledge and research and development experience of the existing core technical personnel are sufficient to lead the pharmaceutical research and development process, consolidate core technology, and promote business development.

In addition, three vice presidents resigned in the past month in the past month. On June 21, Guang Yuyuan issued an announcement that the board of directors received a written resignation report from Zhang Yan and Liang Peng, respectively. The reasons resigned as the vice president, and no longer held any position after resigning. On May 19, Vice President Fu Shuhong just resigned.

Since 2022, 6 executives have left the departure of Guangyuyuan, which is related to the adjustment of Guangyuyuan's architecture. Shanxi Guangyu, the Guangyu Yuanzi company, has changed the business scope -increased the drug Internet information service, and at the same time removed Chinese medicine to remove Chinese medicine, while removing traditional Chinese medicine Drinking production, processing, and sales.

At the end of 2021, Hubei Medicine 19 Provincial Alliance and Guangdong Yahe Pharmaceutical 13 Provincial Alliance Collection opened. In March of this year, the Shandong Internet Chinese Medicinal Materials Trading Center issued the "Notice on the Reporting Reporting Reporting Reporting Reported by Part of the Chinese Medicine Drinking Variety".

Judging from the effectiveness of past drugs and biopharmaceuticals, the collection of traditional Chinese medicine collection on the industry has a profound impact. Traditional Chinese medicine companies have to continue to survive, and the flow of personnel, including executives, is inevitable. Other Chinese medicine leading companies include Pianzi 癀 and China Resources Sanjiu.

2. The pharmaceutical industry needs to be changed

The frequent resignation of pharmaceutical companies can't help but remind people of the large -scale personnel of major pharmaceutical companies in recent times. Does this mean that executives have also ushered in the wave of departure?

Shi Lichen, a well -known strategic marketing expert, did not think that executives ushered in a "wave of departure." "The current policy changes are gradually gradual, which is different from the past policy turns. For example, the country's environmental protection rectification in 2017 is different."

In the future, the trend of changes in the entire pharmaceutical industry is that industrial enterprises and commercial enterprises will become less and less. Like national policies to encourage retail pharmacies to centralize, pharmaceutical companies will gradually become concentrated in the future.

Although the situation of each enterprise is different, the external environment is almost consistent. Whether it is a local pharmaceutical company or a multinational pharmaceutical company, due to the influence of China's medical reform policy to varying degrees, multinational pharmaceutical companies have also experienced senior executives.

Shi Lichen believes that during the transition period, the industry turmoil is inevitable. In the past three or forty years, China's pharmaceutical environment has been stable for too long. Many pharmaceutical companies can sell for decades by one product, and lack of innovation driving force. Instead, stability has become a obstacle to medical innovation, and China's pharmaceutical environment needs to be changed.

In his opinion, the situation of the departure of executives will continue in the future, and the number will be more and more. There may be two cases of senior executives. One is that the operating ability and knowledge structure of many corporate executives are no longer suitable for new market competition.

"For example, under the collection, the market in the hospital is no longer possible. Pharmaceutical companies need to change their minds to be an off -hospital market. Many of the out -of -hospital markets are small and scattered. It is difficult to adapt to the off -court market. In this case, it is difficult to complete the indicator tasks issued by the enterprise, so facing the situation of active or passive resignation. "Shi Lichen said.

The second situation is that due to the impact of collection and the development of innovative drugs, some pharmaceutical companies have lost their future development prospects. Many companies do not do the weaker R & D or R & D capabilities, and the executives will take the initiative to leave. The signal of this release is that the entire pharmaceutical industry in China is in a transition period. It can no longer rely on the inertial business model to operate to the enterprise executives, and to ordinary employees. Sales model, innovative research and development capabilities.

Under the changes in the current policy environment and the influence of the epidemic, whether it is large or small pharmaceutical companies, local pharmaceutical companies, or multinational pharmaceutical companies, the pressure is very high. In today's environment, only by developing innovative drugs can companies survive. Those who are self -proclaimed and do not follow the industry may face the fate of being eliminated.

Editor in charge: octagonal

This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -